{
  "paper_id": "PMC11091288",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11091288/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Figure 1.",
      "caption": "Free DNA from the breast tumor microenvironment enters the circulation. Created with BioRender.com.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/129b/11091288/3dbcfd5108f9/fimmu-15-1355887-g001.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/129b/11091288/3dbcfd5108f9/fimmu-15-1355887-g001.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/129b/11091288/3dbcfd5108f9/fimmu-15-1355887-g001.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/129b/11091288/3dbcfd5108f9/fimmu-15-1355887-g001.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "f1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/129b/11091288/3dbcfd5108f9/fimmu-15-1355887-g001.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC11091288/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/129b/11091288/3dbcfd5108f9/fimmu-15-1355887-g001.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Figure 2.",
      "caption": "The detection process of ctDNA and different research directions within ctDNA can all play a role in breast cancer. Created with BioRender.com.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/129b/11091288/c337857e46a1/fimmu-15-1355887-g002.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/129b/11091288/c337857e46a1/fimmu-15-1355887-g002.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/129b/11091288/c337857e46a1/fimmu-15-1355887-g002.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/129b/11091288/c337857e46a1/fimmu-15-1355887-g002.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "f2",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/129b/11091288/c337857e46a1/fimmu-15-1355887-g002.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC11091288/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/129b/11091288/c337857e46a1/fimmu-15-1355887-g002.jpg"
    },
    "figure_3": {
      "figure_number": "Figure 3",
      "title": "Figure 3.",
      "caption": "Heterogeneity is a major cause of prognostic differences in breast cancers with similar clinical profiles and ctDNA plays an important role at multiple stages in the breast cancer development curve. Created with BioRender.com.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/129b/11091288/c4bd4492de11/fimmu-15-1355887-g003.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/129b/11091288/c4bd4492de11/fimmu-15-1355887-g003.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/129b/11091288/c4bd4492de11/fimmu-15-1355887-g003.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/129b/11091288/c4bd4492de11/fimmu-15-1355887-g003.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "f3",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/129b/11091288/c4bd4492de11/fimmu-15-1355887-g003.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC11091288/images/figure_3.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/129b/11091288/c4bd4492de11/fimmu-15-1355887-g003.jpg"
    }
  },
  "claims": [
    {
      "sentence": "However, in cancer patients, the principal contributors to cfDNA are the components of the tumor microenvironment (TME), which include tumor cells and tumor-infiltrating T lymphocytes (30) (\nFigure 1\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "It is anticipated that these markers will see expanded adoption in clinical settings in the foreseeable future, paving the way for broader clinical utilization (\nFigure 2\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "As a result, ctDNA has the potential to make significant contributions in various aspects of breast cancer management, including screening, diagnosis, prognosis, treatment, and follow-up (\nFigure 3\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "However, in cancer patients, the principal contributors to cfDNA are the components of the tumor microenvironment (TME), which include tumor cells and tumor-infiltrating T lymphocytes (30) (\nFigure 1\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "It is anticipated that these markers will see expanded adoption in clinical settings in the foreseeable future, paving the way for broader clinical utilization (\nFigure 2\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "As a result, ctDNA has the potential to make significant contributions in various aspects of breast cancer management, including screening, diagnosis, prognosis, treatment, and follow-up (\nFigure 3\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "However, in cancer patients, the principal contributors to cfDNA are the components of the tumor microenvironment (TME), which include tumor cells and tumor-infiltrating T lymphocytes (30) (\nFigure 1\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "It is anticipated that these markers will see expanded adoption in clinical settings in the foreseeable future, paving the way for broader clinical utilization (\nFigure 2\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "As a result, ctDNA has the potential to make significant contributions in various aspects of breast cancer management, including screening, diagnosis, prognosis, treatment, and follow-up (\nFigure 3\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "However, in cancer patients, the principal contributors to cfDNA are the components of the tumor microenvironment (TME), which include tumor cells and tumor-infiltrating T lymphocytes (30) (\nFigure 1\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "It is anticipated that these markers will see expanded adoption in clinical settings in the foreseeable future, paving the way for broader clinical utilization (\nFigure 2\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "As a result, ctDNA has the potential to make significant contributions in various aspects of breast cancer management, including screening, diagnosis, prognosis, treatment, and follow-up (\nFigure 3\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "However, in cancer patients, the principal contributors to cfDNA are the components of the tumor microenvironment (TME), which include tumor cells and tumor-infiltrating T lymphocytes (30) (\nFigure 1\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "It is anticipated that these markers will see expanded adoption in clinical settings in the foreseeable future, paving the way for broader clinical utilization (\nFigure 2\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "As a result, ctDNA has the potential to make significant contributions in various aspects of breast cancer management, including screening, diagnosis, prognosis, treatment, and follow-up (\nFigure 3\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "However, in cancer patients, the principal contributors to cfDNA are the components of the tumor microenvironment (TME), which include tumor cells and tumor-infiltrating T lymphocytes (30) (\nFigure 1\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "It is anticipated that these markers will see expanded adoption in clinical settings in the foreseeable future, paving the way for broader clinical utilization (\nFigure 2\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "As a result, ctDNA has the potential to make significant contributions in various aspects of breast cancer management, including screening, diagnosis, prognosis, treatment, and follow-up (\nFigure 3\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "However, in cancer patients, the principal contributors to cfDNA are the components of the tumor microenvironment (TME), which include tumor cells and tumor-infiltrating T lymphocytes (30) (\nFigure 1\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "It is anticipated that these markers will see expanded adoption in clinical settings in the foreseeable future, paving the way for broader clinical utilization (\nFigure 2\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "As a result, ctDNA has the potential to make significant contributions in various aspects of breast cancer management, including screening, diagnosis, prognosis, treatment, and follow-up (\nFigure 3\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "However, in cancer patients, the principal contributors to cfDNA are the components of the tumor microenvironment (TME), which include tumor cells and tumor-infiltrating T lymphocytes (30) (\nFigure 1\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "It is anticipated that these markers will see expanded adoption in clinical settings in the foreseeable future, paving the way for broader clinical utilization (\nFigure 2\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "As a result, ctDNA has the potential to make significant contributions in various aspects of breast cancer management, including screening, diagnosis, prognosis, treatment, and follow-up (\nFigure 3\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "However, in cancer patients, the principal contributors to cfDNA are the components of the tumor microenvironment (TME), which include tumor cells and tumor-infiltrating T lymphocytes (30) (\nFigure 1\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "It is anticipated that these markers will see expanded adoption in clinical settings in the foreseeable future, paving the way for broader clinical utilization (\nFigure 2\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "However, in cancer patients, the principal contributors to cfDNA are the components of the tumor microenvironment (TME), which include tumor cells and tumor-infiltrating T lymphocytes (30) (\nFigure 1\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "It is anticipated that these markers will see expanded adoption in clinical settings in the foreseeable future, paving the way for broader clinical utilization (\nFigure 2\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "As a result, ctDNA has the potential to make significant contributions in various aspects of breast cancer management, including screening, diagnosis, prognosis, treatment, and follow-up (\nFigure 3\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "As a result, ctDNA has the potential to make significant contributions in various aspects of breast cancer management, including screening, diagnosis, prognosis, treatment, and follow-up (\nFigure 3\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 3,
    "claims_count": 30,
    "images_downloaded": 3,
    "tables_filtered": 33
  }
}